Prevalence of age-related macular degeneration in Nakuru, Kenya: a cross-sectional population-based study. [PDF]
, 2013 BACKGROUND: Diseases of the posterior segment of the eye, including age-related macular degeneration (AMD), have recently been recognised as the leading or second leading cause of blindness in several African countries.
Bastawrous, Andrew +5 more
core +6 more sources
Dietary fatty acids and lipoproteins on progression of age-related macular degeneration [PDF]
, 2017 Age-related macular degeneration (AMD) is a medical condition of central loss vision and blindness. Numerous studies have revealed that changes on certain dietary fatty acids (FAs) could have useful for AMD management.
Abia González, María del Rocío +5 more
core +3 more sources
Association of neovascular age-related macular degeneration with migraine
Scientific Reports, 2022 Patients with early onset vascular pathology have been reported to manifest neovascular age-related macular degeneration (AMD). While the blood vessels involved in pathogenesis of migraine remains controversial, it is generally accepted that a major ...
Tung-Mei Kuang +4 more
doaj +1 more source
, 2020 Producción CientíficaABSTRACT: BACKGROUND: The aim of this study was to determine the intra-session repeatability and inter-examiner reproducibility of the colour perimetry technique when assessing in vivo macular pigment optical density in age-related ...
Coco Martín, Rosa María +4 more
core +2 more sources
Treatment as required versus regular monthly treatment in the management of neovascular age-related macular degeneration: a systematic review and meta-analysis [PDF]
, 2015 Background: To investigate whether treatment as required ‘pro re nata’ (PRN) versus regular monthly treatment regimens lead to differences in outcomes in neovascular age-related macular degeneration (nAMD).
Agostini, Hansjuergen +7 more
core +3 more sources
Quantitative Autofluorescence in Non-Neovascular Age Related Macular Degeneration
Biomedicines, 2023 Quantitative autofluorescence (qAF8) level is a presumed surrogate marker of lipofuscin content in the retina. We investigated the changes in the qAF8 levels in non-neovascular AMD. In this prospective cohort study, Caucasians aged ≥50 years with varying
Shruti Chandra +7 more
doaj +1 more source
Complement C3 variant and the risk of age-related macular degeneration [PDF]
, 2007 Background: Age-related macular degeneration is the most common cause of blindness in Western populations. Susceptibility is influenced by age and by genetic and environmental factors.
Armbrecht, AM +16 more
core +1 more source
New Therapies of Neovascular AMD beyond Anti-VEGF Injections
Vision, 2018 Neovascular age-related macular degeneration is a leading cause of vision loss among the aging population. The current standard of care to treat neovascular age-related macular degeneration is inhibiting vascular endothelial growth factor (VEGF) through ...
Greggory M. Gahn, Arshad M. Khanani
doaj +1 more source
Health State Utility Values for Age-Related Macular Degeneration: Review and Advice [PDF]
, 2016 Health state utility values are a major source of uncertainty in economic evaluations of interventions for age-related macular degeneration (AMD). This review identifies and critiques published utility values and methods for eliciting de novo utility ...
Butt, T, Rubin, G, Tufail, A
core +1 more source
Ranibizumab in neovascular age-related macular degeneration
Clinical Interventions in Aging, 2006 Neovascular age-related macular degeneration (AMD) is a visually devastating condition resulting from choroidal neovascularization and secondary photoreceptor loss. Ranibizumab and bevacizumab are medications that target vascular endothelial growth factor (VEGF).
T Eng, Kenneth, Peter J, Kertes
openaire +2 more sources